The whistleblower pharmaceutical sales reps in the Procrit case reinstated in a Massachussetts federal court claim that their careers at Johnson & Johnson's Ortho Biotech unit were based mostly on ...

(CN) – The Supreme Court on Monday refused to block a lawsuit against a Johnson & Johnson subsidiary by salesmen who accused the company of giving kickbacks to doctors for prescribing its anemia drug ...

Several clinical trials of a widely used anemia drug have been halted in the last few weeks after patients developed a higher-than-expected number of blood clots, according to doctors and Johnson & ...

Johnson & Johnson is trimming its sales force for anemia drug Procrit, a top-seller that has lost market share recently due to increased competition from Amgen’s Aranesp. Ortho Biotech Products, the J ...

Dear Dr. Roach: I am a patient with myelofibrosis, and have been under treatment for over three years. At one time I was receiving blood transfusions every three weeks and taking Jakafi (very ...

Documents in a lawsuit filed against Johnson & Johnson by two former salesmen show how the pharmaceutical giant sought to boost sales of its blockbuster anti-anemia drug Procrit by offering contracts ...

Dec. 2, 2005 -- The US Food and Drug Administration (FDA), Amgen Inc, and Ortho Biotech Clinical Affairs, LLC, have notified healthcare professionals via letter regarding revisions to the safety ...

Dec. 9, 2004 -- The U.S. Food and Drug Administration (FDA) and Ortho Biotech Products warned healthcare professionals via letter of important information regarding the safe dosing of epoetin alfa ...

NEW YORK – Johnson & Johnson (JNJ) has sued Amgen (AMGN), accusing the world's largest biotechnology company of hampering sales of J&J's anemia drug, Procrit (search), by using anti-competitive ...

Members of the FDA’s Oncologic Drugs Advisory Committee expressed concerns at a May meeting that DTC advertising of Amgen’s Aranesp and Johnson & Johnson’s Procrit have given patients a lopsided ...

Please provide your email address to receive an email when new articles are posted on . The FDA today approved epoetin alfa-epbx, the first epoetin alfa biosimilar, for the treatment of anemia caused ...